Sino Biopharmaceutical Limited (SMZ1.F)

0,3026 +0,0025 (+0,83%) Alla chiusura: 08:09AM CEST

Sino Biopharmaceutical Limited

Unit 09, Office Tower
41st Floor, Room 4109 Convention Plaza 1 Harbour Road
Wan Chai
Hong Kong
852 2802 9886
https://www.sinobiopharm.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 25.806

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Y. Y. Tse	Executive Chairwoman of the Board	6,38M	N/D	1992
Mr. Eric S. Y. Tse	CEO & Executive Director	6,38M	N/D	1996
Mr. Ping Tse	Founder & Senior Executive Vice Chairman	6,36M	N/D	1952
Ms. Cheung Ling Cheng	Executive Vice Chairwoman of the Board	5,54M	N/D	1964
Mr. Zhoushan Tian	Executive Director	244,89k	N/D	1964
Mr. Hsin Tse	Senior VP & Executive Director	822,98k	N/D	1970
Ms. Chun Ling Li	Chief Financial Officer	N/D	N/D	1972
Mr. Song Jin	Vice President of Public Affairs, Medicines Policies & ESG	N/D	N/D	1976
Mr. Sean Chen	Chief Strategy Officer	N/D	N/D	1978
Orphanides George	Chief Scientific Advisor of invoX	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji; cardio-cerebral vascular medicines, such as irbesartan and hydrochlorothiazide tablets under the brand Yilunping and beraprost sodium tablets under the brand Kaina; and biosimilar medicines comprising adalimumab solution for injection under the brand Taibowei. In addition, the company develops oncology drugs, include benmelstobart, D-1553, TQ-B3139, and TQ-B3101; liver disease drugs, such as Lanifibranor and TQA2225/AP025; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Governance aziendale

L'ISS Governance QualityScore di Sino Biopharmaceutical Limited al 1 giugno 2024 è 6. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 1; diritti degli azionisti: 7; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.